The Division of Genitourinary Pathology consists of Dr. Debra Zynger (director), Dr. Larry DeRenne, Dr. Steve Moore, Dr. Anil Parwani and Dr. Gary Tozbikian. The division has a wide diversity of cases and large oncologic volume including approximately 300 nephrectomy, 200 robotic prostatectomy, 100 cystectomy, 40 orchiectomy, 40 adrenalectomy and 10 penectomy tumor resections per year.
Cases are complex and advanced tumors are not infrequent. For example, 22% of robotic prostatectomies have positive lymph nodes (pN1) and 45% are pT3.
Diagnostic immunohistochemical tests that have been implemented since 2009 that are used by the Division of Genitourinary Pathology include laminin, CAIX, AR, OCT3/4, CD44s, GATA3, PAX8, NKX3.1, p40, the double stains CK5/p53 and CK5/CK7 and an inhouse cocktail of AMACR/p63/CK5.
The Division of Genitourinary Pathology participates in several monthly interdisciplinary meetings attended by Pathology, Urology, Genitourinary Oncology and Radiation Oncology including Urologic Oncology Tumor Board and Genitourinary Oncology Clinical Trial Update.
Subspecialty sign-out allows for in-depth teaching opportunities. Trainees specializing in Pathology or related disciplines such as Urology can take a 1 month resident or medical student rotation in Genitourinary Surgical Pathology. We also participate in the required 3rd year medical student surgical pathology clerkship experience.
The Genitourinary Pathology division is actively involved in research projects and frequently collaborates with members of the departments of Urology, Oncology, Radiology and Radiation Oncology.